Africa Medical Cannabis Market Size to Surpass USD 8.2 Billion by 2034, at a CAGR of 17.24%

Africa Medical Cannabis Market Overview

Market Size in 2025: USD 1.9 Billion

Market Size in 2034: USD 8.2 Billion

Market Growth Rate 2026-2034: 17.24%

According to IMARC Group's latest research publication, "Africa Medical Cannabis Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034", The Africa medical cannabis market size reached USD 1.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2034, exhibiting a growth rate (CAGR) of 17.24% during 2026-2034.

How AI is Reshaping the Future of Africa Medical Cannabis Market

● AI tools in South African cannabis facilities optimise growing conditions, helping producers deliver consistent medical-grade yields for export markets.

● Malawi's $10 million processing plant, backed by government partners, stands to generate up to $300 million yearly once AI-supported extraction scales.

● Precision agriculture platforms using AI raise crop yields by 25-30 percent, giving African medical cannabis farmers a competitive edge in quality control.

● Companies like African Harvest deploy AI-controlled systems in grow pods, making GMP-compliant medical cannabis production more accessible to local operators.

● Government legalisation schemes across Lesotho, South Africa and Zimbabwe pair with AI research to speed personalised cannabis therapies for patients.

Grab a sample PDF of this report: https://www.imarcgroup.com/africa-medical-cannabis-market/requestsample

Africa Medical Cannabis Market Trends & Drivers:

The rising prevalence of chronic illnesses across the continent, including cancer, epilepsy, HIV-related conditions, and persistent pain disorders, continues to expand demand for alternative therapeutic options. Growing public and clinical awareness of the plant's medicinal properties further supports this shift, as patients and healthcare providers increasingly recognize its potential in symptom management. These health-related factors are steadily encouraging greater acceptance and integration of medical cannabis into treatment approaches throughout the region.

Supportive government policies in multiple African nations are enabling licensed cultivation, processing, and distribution strictly for medical and scientific purposes. Favorable climatic conditions combined with abundant arable land make the continent particularly suited to high-quality production, attracting both domestic and foreign investment. This regulatory progress is helping transform traditional informal cultivation into structured, export-oriented medical supply chains that meet international pharmaceutical standards.

Partnerships between local producers and global pharmaceutical or research entities are strengthening supply chains and driving product innovation. Concurrent expansion of the broader pharmaceutical sector, along with increased research into cannabis-based formulations and health supplements, is further accelerating market development. These collaborative and industry-wide efforts are positioning medical cannabis as an emerging component of Africa's healthcare and agricultural landscapes.

Ask analyst of customized report: https://www.imarcgroup.com/request?type=report&id=3213&flag=E

Africa Medical Cannabis Industry Segmentation:

Breakup by Species:

● Cannabis Indica
● Sativa
● Hybrid

Breakup by Derivative:

● Tetrahydrocannabinol
● Others

Breakup by Route of Administration:

● Capsules and Oral Solutions
● Vaporizers
● Smoking
● Topicals
● Others

Breakup by Application:

● Cancer
● HIV/AIDS
● Epilepsy
● Pain
● Others

Breakup by End User:

● Pharmaceutical Industry
● Research and Development Centers
● Others

Breakup by Country:

● Lesotho
● Zimbabwe
● South Africa
● Ghana
● Zambia
● Malawi

Recent News and Developments in Africa Medical Cannabis Market

● August 2026: Rwanda advances commercial medical cannabis production under a new pharmaceutical policy, with licensing focused solely on medicinal and therapeutic products for export and research while maintaining recreational bans.

● July 2026: Zimbabwe's Ivory Medical launches CannaQure oils using supercritical carbon dioxide extraction from local plants, offered in isolate and full-spectrum forms with under 1% for enhanced bioavailability via sublingual delivery.

● August 2026: Ghana grants its first pilot licences to two companies for medicinal and industrial cannabis cultivation limited to 0.3%, enabling regulated production aimed at jobs, investment and research under strict oversight.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302

This release was published on openPR.